about
New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in gliomaLB100, a small molecule inhibitor of PP2A with potent chemo- and radio-sensitizing potentialAnthracyclines suppress pheochromocytoma cell characteristics, including metastasis, through inhibition of the hypoxia signaling pathway.The p38 signaling pathway mediates quiescence of glioma stem cells by regulating epidermal growth factor receptor traffickingMutant glucocerebrosidase in Gaucher disease recruits Hsp27 to the Hsp90 chaperone complex for proteasomal degradationActivation of hypoxia signaling induces phenotypic transformation of glioma cells: implications for bevacizumab antiangiogenic therapyProtein Phosphatase 2A Inhibition with LB100 Enhances Radiation-Induced Mitotic Catastrophe and Tumor Growth Delay in Glioblastoma.Inhibition of protein phosphatase 2A with the small molecule LB100 overcomes cell cycle arrest in osteosarcoma after cisplatin treatment.Characterization of the blood-brain barrier of metastatic and primary malignant neoplasms.De novo VHL germline mutation detected in a patient with mild clinical phenotype of von Hippel-Lindau disease.First report of bilateral pheochromocytoma in the clinical spectrum of HIF2A-related polycythemia-paraganglioma syndrome.HIF2A gain-of-function mutations detected in duodenal gangliocytic paraganglioma.Application of Peptide Nucleic Acid-based Assays Toward Detection of Somatic MosaicismSomatic IDH1 mutation in a pituitary adenoma of a patient with Maffucci syndrome.Celastrol increases glucocerebrosidase activity in Gaucher disease by modulating molecular chaperones.Tumor derived vasculogenesis in von Hippel-Lindau disease-associated tumors.Novel homozygous VHL mutation in exon 2 is associated with congenital polycythemia but not with cancer.Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair.ZEB1 expression is increased in IDH1-mutant lower-grade gliomas.Vorinostat suppresses hypoxia signaling by modulating nuclear translocation of hypoxia inducible factor 1 alpha.Novel Targeting of Transcription and Metabolism in Glioblastoma.Evaluating In Vitro DNA Damage Using Comet Assay.Targeting NAD+/PARP DNA repair pathway as a novel therapeutic approach to SDHB-mutated cluster I pheochromocytoma and paraganglioma.A novel splicing site IRP1 somatic mutation in a patient with pheochromocytoma and JAK2V617F positive polycythemia vera: a case report.Acetylation within the N- and C-terminal domains of Src regulate distinct roles of STAT3-mediated tumorigenesis.Brusatol, an NRF2 inhibitor for future cancer therapeutic.Therapeutic targeting of SDHB-mutated pheochromocytoma/paraganglioma with pharmacologic ascorbic acidBlockade of Glutathione Metabolism in IDH1-Mutated GliomaNonmosaic somatic HIF2A mutations associated with late onset polycythemia-paraganglioma syndrome: Newly recognized subclass of polycythemia-paraganglioma syndromeTargeting IDH1-Mutated Malignancies with NRF2 BlockadeA Transgenic Mouse Model of Pacak⁻Zhuang Syndrome with An Epas1 Gain-of-Function MutationTriptolide suppresses IDH1-mutated malignancy via Nrf2-driven glutathione metabolismPheochromocytomas and Paragangliomas: From Genetic Diversity to Targeted TherapiesCombination of PARP inhibitor and temozolomide to suppress chordoma progressionTargeting NRF2-Governed Glutathione Synthesis for SDHB-Mutated Pheochromocytoma and Paraganglioma
P50
Q26863394-2E653B48-A8ED-4B59-B051-2E98315F0E12Q26865711-5FC95C1D-976D-4F8E-A684-6F57A1EFC4D4Q33618312-F2AF2472-6CA9-4360-B952-7AB84B155932Q33779457-4A908626-B083-46C7-B1D5-B553DE5E53E8Q35037986-23A00C8B-6227-4131-8471-0FAC4DEED86FQ35828461-7D40A2E4-EBEB-4393-8AB8-BF5CCDA01BA1Q35836388-1E9A1DC7-C03C-41A5-A451-B1892FE97E19Q36180744-8BD60FCA-9604-4A27-A463-06ABE2C9A62FQ36560327-3216C369-7788-43F7-B9D7-C072516C5261Q36567242-F1684EF8-1EB6-40A1-8DA8-104322CA24C4Q36817266-3C9FB5D7-91E2-4DDB-ACA3-EC3BBCBD1DD0Q36984534-015A5285-2ADB-4528-933C-686557814364Q37238917-7C5191CE-0348-44A9-B37D-688F3FE4A03AQ37435322-440B6822-10C8-416F-975D-70BF526FA142Q37475206-6936364B-39B8-4FBF-B947-48F2571E16B4Q37587468-DC4C159F-BC17-4EC7-8A73-DB1D1E1699A8Q37685596-48298FDE-58C7-43CE-9682-FFCBDC6A8883Q38405744-58BD51B6-05E4-44B8-9CA3-49D33DC49A15Q38438838-120DAD14-6BC8-447D-BF5E-6BE3E812B74EQ41347745-C4C27A5E-D87A-48E9-AF5B-69FAB3C9E0C2Q47279320-E3066740-C369-4577-8078-A08177E9936AQ50061350-7E520C63-F12F-43CE-B335-769F4409F991Q52325957-AB11DC3F-DB6D-4C33-A83F-F527C572760EQ52657647-D65B3C0D-2D0C-4F10-A3AB-D29F862311DEQ52659573-AEE19D66-B3AF-4C3A-979F-E5A9305FD1ADQ64955240-A88D00AA-86BE-4899-A557-C7C5EE6578D9Q90169753-85E4590D-F898-47B5-9284-9DCA98308FE4Q90239465-3122994F-55FC-45CE-9260-3E4E7EE25E30Q91050339-41D63C47-818B-4767-8263-A95D0CC22F2AQ91547097-595FBD5E-F678-4090-8191-4CEA0F5AD7B1Q92042739-FE317F4F-B6B5-402C-890E-C290C1728AA1Q92091477-B68886BE-3923-4D88-997C-FA3429A9A735Q92702306-2C9CBA5E-99C8-42E7-AFE3-A7B24E3EE028Q92762324-08ED7959-855C-49BF-80F5-A90E1C38EA80Q92922896-0E917348-3FD3-433D-A0E7-B4FFF5ECF8DE
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Chunzhang Yang
@en
Chunzhang Yang
@nl
type
label
Chunzhang Yang
@en
Chunzhang Yang
@nl
prefLabel
Chunzhang Yang
@en
Chunzhang Yang
@nl
P31
P496
0000-0001-6433-0867